College of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China; The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, Zhejiang, China.
The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, Zhejiang, China; School of Life Sciences, Tianjin University, Tianjin, China.
Pharmacol Res. 2022 Aug;182:106357. doi: 10.1016/j.phrs.2022.106357. Epub 2022 Jul 19.
Signal transducer and activator of transcription 3 (STAT3) plays a critical role in signal transmission from the plasma membrane to the nucleus, regulating the expression of genes involved in essential cell functions and controlling the processes of cell cycle progression and apoptosis. Thus, STAT3 has been elucidated as a promising target for developing anticancer drugs. Many natural products have been reported to inhibit the STAT3 signaling pathway during the past two decades and have exhibited significant anticancer activities in vitro and in vivo. However, there is no FDA-approved STAT3 inhibitor yet. The major mechanisms of these natural product inhibitors of the STAT3 signaling pathway include targeting the upstream regulators of STAT3, directly binding to the STAT3 SH2 domain and inhibiting its activation, inhibiting STAT3 phosphorylation and/or dimerization, and others. In the present review, we have systematically discussed the development of these natural product inhibitors of STAT3 signaling pathway as well as their in vitro and in vivo anticancer activity and mechanisms of action. Outlooks and perspectives on the associated challenges are provided as well.
信号转导子和转录激活子 3(STAT3)在将信号从质膜传递到核内的过程中起着关键作用,调节参与基本细胞功能的基因的表达,并控制细胞周期进展和细胞凋亡的过程。因此,STAT3 已被阐明为开发抗癌药物的有前途的靶标。在过去的二十年中,已经有许多天然产物被报道能够抑制 STAT3 信号通路,并在体外和体内表现出显著的抗癌活性。然而,目前还没有 FDA 批准的 STAT3 抑制剂。这些抑制 STAT3 信号通路的天然产物抑制剂的主要机制包括靶向 STAT3 的上游调节剂,直接与 STAT3 的 SH2 结构域结合并抑制其激活,抑制 STAT3 的磷酸化和/或二聚化,以及其他机制。在本综述中,我们系统地讨论了这些抑制 STAT3 信号通路的天然产物抑制剂的发展,以及它们在体外和体内的抗癌活性和作用机制。还提供了相关挑战的展望和观点。